A Phase 2 interventional study of Pneumococcal Conjugate Vaccine - formulation 1-SP0202-IIb and Pneumococcal Conjugate Vaccine - formulation 2-SP0202-VI in Pneumococcal Immunization, sponsored by Sanofi. Completed at 17 sites in United States. Open to participants aged 50 Years to 84 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-08.
Sponsored by Sanofi · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Primary Objectives:
The duration of each participant's participation was approximately 6 months.
Sanofi is the lead sponsor of 1,559 studies on the registry; 90 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
- Aged 50 to 84 years on the day of inclusion .
Exclusion criteria:
The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
One dose at Day 1
Biological: Pneumococcal Conjugate Vaccine - formulation 1-SP0202-IIb
One dose at Day 1
Biological: Pneumococcal Conjugate Vaccine - formulation 2-SP0202-VI
One dose at Day 1
Biological: Pneumococcal Conjugate Vaccine - formulation 3-SP0202-VII
One dose at Day 1
Biological: Pneumococcal 13 - valent conjugate vaccine-Prevnar 13
One dose at Day 1
Biological: Pneumococcal Vaccine Polyvalent-Pneumovax 23
Pharmaceutical form:Suspension for injection Route of administration: intramuscular
Pharmaceutical form:Suspension for injection Route of administration: intramuscular
Pharmaceutical form:Suspension for injection Route of administration: intramuscular
Pharmaceutical form:Suspension for injection Route of administration: intramuscular
Pharmaceutical form:Solution for injection Route of administration: intramuscular
Geometric Mean Titers (GMTs) of Pneumococcal Serotypes Using Serotype-Specific MOPA
The GMs for serotype specific OPA titers were measured using MOPA which was used to evaluate the opsonophagocytic index (50% killing) of pneumococcal anti-capsular polysaccharide antibodies in human serum samples following vaccination. Titers were expressed in terms of 1/dilution.
Time frame: Post-vaccination at Day 31
Geometric Mean Titers Ratio of Pneumococcal Serotypes Using Serotype-Specific MOPA
The GMs for serotype specific OPA titers were measured using MOPA which was used to evaluate the opsonophagocytic index (50% killing) of pneumococcal anti-capsular polysaccharide antibodies in human serum samples following vaccination. Ratio was calculated as post-vaccination titer at Day 31 to pre-vaccination titer at Day 1.
Time frame: Pre-vaccination at Baseline (Day 1) and Post-vaccination at Day 31
Geometric Mean Concentrations (GMCs) of Pneumococcal Serotypes Using Serotype-Specific IgG ECL
The GMCs for serotype specific pneumococcal IgG antibodies were measured using ECL, a multiplexed serological assay which allowed for the simultaneous quantification of human IgG against pneumococcal polysaccharide antigens.
Time frame: Post-vaccination at Day 31
Geometric Mean Concentrations Ratio of Pneumococcal Serotypes Using Serotype-Specific IgG ECL
The GMCs for serotype specific pneumococcal IgG antibodies were measured using ECL, a multiplexed serological assay which allowed for the simultaneous quantification of human IgG against pneumococcal polysaccharide antigens. Ratio was calculated as post-vaccination titer at Day 31 to pre-vaccination titer at Day 1.
Time frame: Pre-vaccination at Baseline (Day 1) and Post-vaccination at Day 31
Number of Participants With Immediate Unsolicited Systemic Adverse Events (AEs)
An unsolicited AE was an observed AE that did not fulfill the conditions of solicited reactions, i.e., pre-listed in the CRF in terms of diagnosis and/or onset window post-vaccination. Systemic AEs were all AEs that were not injection or administration site reactions.
Time frame: Within 30 minutes post-vaccination
Number of Participants With Solicited Injection Site Reactions
A solicited reaction was an "expected" adverse reaction (AR) (sign or symptom) observed and reported under the conditions (nature and onset) pre-listed in the protocol and CRF. An injection site reaction was an AR at and around the injection site. Solicited injection site reactions included injection site pain, injection site erythema and injection site swelling.
Time frame: Up to 7 Days post-vaccination (Day 8)
Number of Participants With Solicited Systemic Reactions
A solicited reaction was an "expected" AR (sign or symptom) observed and reported under the conditions (nature and onset) pre-listed in the protocol and CRF. Solicited systemic reactions included fever, headache, malaise, myalgia, arthralgia and shivering.
Time frame: Up to 7 Days post-vaccination (Day 8)
Number of Participants With Unsolicited AEs
An unsolicited AE was an observed AE that did not fulfill the conditions of solicited reactions, i.e., pre-listed in the CRF in terms of diagnosis and/or onset window post-vaccination.
Time frame: Within 30 days post-vaccination
Number of Participants With Serious Adverse Events (SAEs) and Adverse Event of Special Interest (AESIs)
An SAE was any untoward medical occurrence that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event. An AESI was defined as one of scientific and medical concern specific to the Sponsor's study intervention or program, for which ongoing monitoring and rapid communication by the investigator to the Sponsor could be appropriate. AESI included analyphylaxis.
Time frame: From the study vaccine administration (Day 1) until the end of 6-Month follow-up, 181 days
This study was conducted at 17 investigational sites in United States between 08 Oct 2020 to 20 Jan 2022.
| Milestone | Group 1: SP0202-IIb | Group 2: SP0202-VI | Group 3: SP0202-VII | Group 4: Prevnar 13 | Group 5: Pneumovax 23 |
|---|---|---|---|---|---|
| Started | 151 | 151 | 149 | 149 | 150 |
| Safety analysis set (safas) population | 151 | 151 | 148 | 149 | 150 |
| Completed | 148 | 148 | 141 | 147 | 148 |
| Not completed | 3 | 3 | 8 | 2 | 2 |
| Withdrew: Adverse event | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Protocol deviation | 1 | 1 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 2 | 1 | 3 | 1 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 | 3 | 1 | 1 |
The GMs for serotype specific OPA titers were measured using MOPA which was used to evaluate the opsonophagocytic index (50% killing) of pneumococcal anti-capsular polysaccharide antibodies in human serum samples following vaccination. Titers were expressed in terms of 1/dilution.
| Titer | Group 1: SP0202-IIb | Group 2: SP0202-VI | Group 3: SP0202-VII | Group 4: Prevnar 13 | Group 5: Pneumovax 23 |
|---|---|---|---|---|---|
| Serotype 1 | 128 (92.5 to 177) | 127 (90.3 to 178) | 158 (113 to 220) | 254 (183 to 353) | 289 (213 to 392) |
| Serotype 3 | 136 (109 to 170) | 217 (176 to 269) | 263 (214 to 323) | 157 (126 to 196) | 177 (142 to 221) |
| Serotype 4 | 1494 (1175 to 1900) | 1306 (1029 to 1658) | 2134 (1675 to 2719) | 2941 (2360 to 3664) | 1873 (1415 to 2480) |
| Serotype 5 | 241 (166 to 349) | 230 (160 to 330) | 201 (143 to 281) | 536 (378 to 760) | 377 (272 to 523) |
| Serotype 6A | 2931 (2143 to 4010) | 3074 (2389 to 3957) | 2672 (1923 to 3714) | 3350 (2418 to 4641) | 443 (288 to 681) |
| Serotype 6B | 3699 (2857 to 4788) | 3582 (2763 to 4645) | 3479 (2595 to 4664) | 5122 (3916 to 6699) | 2153 (1561 to 2969) |
| Serotype 7F | 3487 (2811 to 4326) | 2841 (2262 to 3568) | 2403 (1878 to 3074) | 4253 (3309 to 5466) | 2250 (1721 to 2943) |
| Serotype 9V | 826 (607 to 1123) | 828 (614 to 1117) | 986 (700 to 1388) | 1641 (1274 to 2114) | 1159 (863 to 1556) |
| Serotype 14 | 3756 (2995 to 4709) | 4407 (3385 to 5737) | 3244 (2421 to 4349) | 3675 (2904 to 4650) | 3999 (3099 to 5161) |
| Serotype 18C | 905 (676 to 1210) | 802 (590 to 1090) | 1025 (756 to 1390) | 1929 (1460 to 2548) | 1177 (875 to 1585) |
| Serotype 19A | 2067 (1719 to 2485) | 3395 (2796 to 4123) | 3462 (2771 to 4324) | 4417 (3537 to 5515) | 2261 (1841 to 2776) |
| Serotype 19F | 897 (702 to 1145) | 1773 (1406 to 2236) | 1678 (1336 to 2108) | 1525 (1165 to 1997) | 983 (742 to 1303) |
| Serotype 23F | 1999 (1478 to 2704) | 1576 (1153 to 2153) | 1701 (1284 to 2255) | 1792 (1311 to 2450) | 488 (319 to 747) |
| Serotype 8 | 1363 (1110 to 1674) | 1377 (1129 to 1680) | 1486 (1207 to 1829) | 74.8 (52.3 to 107) | 2039 (1664 to 2499) |
| Serotype 9N | 3656 (2988 to 4474) | 3858 (3145 to 4733) | 4207 (3430 to 5160) | 1082 (806 to 1453) | 6096 (4837 to 7682) |
| Serotype 10A | 3501 (2689 to 4557) | 2856 (2190 to 3724) | 2811 (2047 to 3860) | 104 (64.3 to 167) | 3011 (2060 to 4399) |
| Serotype 11A | 475 (354 to 637) | 438 (324 to 594) | 318 (226 to 448) | 18.3 (13.0 to 25.6) | 390 (285 to 534) |
| Serotype 12F | 3492 (2587 to 4714) | 3917 (3116 to 4925) | 3117 (2311 to 4203) | 8.31 (6.19 to 11.2) | 1345 (914 to 1980) |
| Serotype 15B | 4930 (3641 to 6677) | 4823 (3588 to 6484) | 3613 (2541 to 5138) | 160 (112 to 230) | 3346 (2409 to 4648) |
| Serotype 22F | 5253 (4147 to 6653) | 4639 (3587 to 6001) | 4858 (3683 to 6406) | 62.5 (42.4 to 92.1) | 1906 (1456 to 2495) |
| Serotype 33F | 7313 (5890 to 9078) | 8324 (6488 to 10680) | 7641 (6205 to 9410) | 1201 (898 to 1605) | 15082 (11551 to 19692) |
The GMs for serotype specific OPA titers were measured using MOPA which was used to evaluate the opsonophagocytic index (50% killing) of pneumococcal anti-capsular polysaccharide antibodies in human serum samples following vaccination. Ratio was calculated as post-vaccination titer at Day 31 to pre-vaccination titer at Day 1.
| Ratio | Group 1: SP0202-IIb | Group 2: SP0202-VI | Group 3: SP0202-VII | Group 4: Prevnar 13 | Group 5: Pneumovax 23 |
|---|---|---|---|---|---|
| Serotype 1 | 8.40 (6.28 to 11.2) | 10.5 (7.95 to 14.0) | 9.79 (7.15 to 13.4) | 21.3 (15.6 to 29.0) | 19.1 (14.4 to 25.3) |
| Serotype 3 | 7.06 (5.55 to 8.99) | 12.9 (10.1 to 16.4) | 13.7 (10.7 to 17.4) | 8.52 (6.71 to 10.8) | 9.52 (7.56 to 12.0) |
| Serotype 4 | 20.7 (14.7 to 29.3) | 28.8 (20.6 to 40.3) | 33.0 (22.2 to 49.2) | 58.9 (41.2 to 84.1) | 25.7 (18.2 to 36.4) |
| Serotype 5 | 15.2 (11.0 to 21.0) | 19.5 (14.3 to 26.7) | 12.2 (9.10 to 16.4) | 37.4 (26.9 to 52.1) | 24.2 (18.2 to 32.2) |
| Serotype 6A | 60.8 (42.8 to 86.5) | 69.4 (48.3 to 99.8) | 59.2 (40.9 to 85.8) | 79.1 (54.4 to 115) | 9.18 (6.34 to 13.3) |
| Serotype 6B | 29.1 (20.6 to 41.2) | 25.7 (18.1 to 36.6) | 29.2 (19.5 to 43.6) | 49.3 (34.8 to 69.7) | 16.6 (11.5 to 23.8) |
| Serotype 7F | 50.8 (32.8 to 78.9) | 49.0 (32.5 to 73.7) | 24.0 (14.9 to 38.7) | 79.1 (51.6 to 121) | 31.0 (21.0 to 45.8) |
| Serotype 9V | 9.50 (7.01 to 12.9) | 9.90 (7.20 to 13.6) | 12.7 (8.90 to 18.0) | 17.2 (12.2 to 24.1) | 10.6 (7.78 to 14.4) |
| Serotype 14 | 7.44 (5.25 to 10.5) | 14.3 (9.69 to 21.0) | 8.44 (5.68 to 12.5) | 10.1 (7.03 to 14.6) | 9.05 (6.46 to 12.7) |
| Serotype 18C | 17.0 (12.4 to 23.3) | 20.6 (15.0 to 28.2) | 18.9 (13.3 to 27.0) | 43.1 (31.1 to 59.8) | 22.1 (16.3 to 30.0) |
| Serotype 19A | 7.36 (5.77 to 9.38) | 13.1 (10.3 to 16.8) | 11.5 (8.66 to 15.3) | 15.5 (11.4 to 21.0) | 7.88 (6.26 to 9.91) |
| Serotype 19F | 13.1 (9.45 to 18.2) | 30.7 (21.9 to 43.0) | 20.8 (15.0 to 29.0) | 26.6 (19.0 to 37.1) | 17.2 (12.5 to 23.7) |
| Serotype 23F | 45.2 (31.0 to 65.9) | 43.0 (29.0 to 63.8) | 43.9 (29.6 to 65.1) | 45.5 (32.2 to 64.4) | 11.6 (7.99 to 16.8) |
| Serotype 8 | 18.6 (13.5 to 25.6) | 24.1 (17.7 to 32.8) | 24.0 (16.3 to 35.3) | 1.37 (1.14 to 1.65) | 37.6 (27.8 to 50.8) |
| Serotype 9N | 8.90 (6.29 to 12.6) | 12.8 (8.90 to 18.4) | 11.5 (7.88 to 16.8) | 2.84 (2.12 to 3.79) | 14.6 (10.7 to 20.0) |
| Serotype 10A | 24.2 (16.3 to 35.8) | 24.7 (16.5 to 36.9) | 20.8 (13.4 to 32.3) | 1.05 (0.932 to 1.19) | 22.9 (16.1 to 32.7) |
| Serotype 11A | 14.8 (10.4 to 21.0) | 15.9 (11.1 to 22.6) | 9.28 (6.46 to 13.3) | 0.964 (0.786 to 1.18) | 13.7 (9.64 to 19.5) |
| Serotype 12F | 240 (163 to 354) | 252 (181 to 353) | 167 (106 to 263) | 0.975 (0.870 to 1.09) | 102 (67.7 to 153) |
| Serotype 15B | 30.1 (20.8 to 43.6) | 34.3 (23.3 to 50.5) | 20.7 (14.1 to 30.4) | 1.21 (0.997 to 1.47) | 22.8 (16.1 to 32.1) |
| Serotype 22F | 39.0 (27.2 to 56.1) | 41.4 (28.5 to 60.3) | 38.5 (25.4 to 58.3) | 0.878 (0.679 to 1.14) | 21.0 (15.1 to 29.1) |
| Serotype 33F | 4.21 (3.27 to 5.41) | 6.27 (4.72 to 8.32) | 4.36 (3.45 to 5.52) | 0.931 (0.871 to 0.995) | 10.4 (7.76 to 13.9) |
The GMCs for serotype specific pneumococcal IgG antibodies were measured using ECL, a multiplexed serological assay which allowed for the simultaneous quantification of human IgG against pneumococcal polysaccharide antigens.
| mcg/mL | Group 1: SP0202-IIb | Group 2: SP0202-VI | Group 3: SP0202-VII | Group 4: Prevnar 13 | Group 5: Pneumovax 23 |
|---|---|---|---|---|---|
| Serotype 1 | 2.98 (2.29 to 3.88) | 3.28 (2.59 to 4.17) | 4.17 (3.29 to 5.28) | 5.93 (4.49 to 7.85) | 7.43 (5.75 to 9.60) |
| Serotype 3 | 0.746 (0.616 to 0.903) | 0.977 (0.818 to 1.17) | 1.22 (1.01 to 1.49) | 0.899 (0.738 to 1.10) | 0.858 (0.717 to 1.03) |
| Serotype 4 | 1.97 (1.60 to 2.43) | 1.63 (1.32 to 2.00) | 2.27 (1.81 to 2.84) | 3.28 (2.61 to 4.12) | 1.72 (1.38 to 2.13) |
| Serotype 5 | 2.35 (1.78 to 3.10) | 2.16 (1.62 to 2.87) | 2.16 (1.68 to 2.78) | 4.34 (3.20 to 5.90) | 3.98 (3.09 to 5.12) |
| Serotype 6A | 6.04 (4.45 to 8.22) | 5.00 (3.83 to 6.54) | 4.83 (3.57 to 6.54) | 7.89 (5.90 to 10.5) | 1.53 (1.16 to 2.02) |
| Serotype 6B | 5.73 (4.17 to 7.89) | 3.62 (2.66 to 4.93) | 4.37 (3.22 to 5.95) | 6.45 (4.92 to 8.45) | 2.47 (1.86 to 3.28) |
| Serotype 7F | 6.56 (5.23 to 8.22) | 5.56 (4.58 to 6.75) | 5.35 (4.30 to 6.65) | 10.1 (8.01 to 12.6) | 4.23 (3.34 to 5.35) |
| Serotype 9V | 2.91 (2.29 to 3.72) | 3.17 (2.52 to 4.00) | 4.31 (3.43 to 5.41) | 5.30 (4.20 to 6.68) | 3.48 (2.75 to 4.41) |
| Serotype 14 | 12.4 (9.88 to 15.7) | 10.5 (8.21 to 13.6) | 9.52 (7.34 to 12.3) | 10.5 (8.22 to 13.4) | 14.6 (11.2 to 19.0) |
| Serotype 18C | 5.50 (4.44 to 6.82) | 5.39 (4.39 to 6.62) | 5.41 (4.44 to 6.59) | 10.3 (8.15 to 13.1) | 5.44 (4.34 to 6.81) |
| Serotype 19A | 7.41 (6.03 to 9.10) | 11.7 (9.16 to 15.1) | 10.9 (8.41 to 14.2) | 18.3 (14.4 to 23.2) | 7.59 (6.05 to 9.52) |
| Serotype 19F | 3.77 (2.92 to 4.87) | 8.35 (6.22 to 11.2) | 7.03 (5.30 to 9.33) | 9.38 (7.16 to 12.3) | 4.47 (3.40 to 5.88) |
| Serotype 23F | 7.35 (5.56 to 9.72) | 5.52 (4.26 to 7.13) | 6.59 (5.05 to 8.61) | 6.99 (5.33 to 9.17) | 3.02 (2.31 to 3.96) |
| Serotype 8 | 7.14 (5.75 to 8.87) | 6.25 (5.09 to 7.68) | 6.23 (4.98 to 7.80) | 0.935 (0.703 to 1.24) | 9.84 (8.14 to 11.9) |
| Serotype 9N | 5.26 (4.06 to 6.81) | 4.50 (3.55 to 5.71) | 6.54 (5.09 to 8.40) | 1.60 (1.20 to 2.12) | 6.41 (5.10 to 8.06) |
| Serotype 10A | 7.16 (5.37 to 9.55) | 9.48 (7.10 to 12.6) | 7.37 (5.39 to 10.1) | 1.06 (0.840 to 1.35) | 9.11 (6.83 to 12.1) |
| Serotype 11A | 4.85 (3.99 to 5.89) | 4.91 (4.08 to 5.89) | 4.27 (3.51 to 5.20) | 0.884 (0.745 to 1.05) | 3.88 (3.19 to 4.72) |
| Serotype 12F | 2.18 (1.58 to 3.02) | 2.09 (1.55 to 2.83) | 1.90 (1.41 to 2.55) | 0.190 (0.158 to 0.228) | 1.03 (0.780 to 1.36) |
| Serotype 15B | 13.4 (10.5 to 17.2) | 16.3 (12.8 to 20.8) | 14.8 (11.7 to 18.8) | 1.84 (1.42 to 2.39) | 13.6 (10.8 to 17.2) |
| Serotype 22F | 3.57 (2.88 to 4.44) | 4.02 (3.20 to 5.05) | 3.78 (3.03 to 4.71) | 0.350 (0.283 to 0.433) | 2.41 (1.93 to 3.00) |
| Serotype 33F | 7.98 (6.19 to 10.3) | 9.15 (7.42 to 11.3) | 7.75 (6.18 to 9.72) | 1.50 (1.21 to 1.85) | 16.4 (12.8 to 21.1) |
The GMCs for serotype specific pneumococcal IgG antibodies were measured using ECL, a multiplexed serological assay which allowed for the simultaneous quantification of human IgG against pneumococcal polysaccharide antigens. Ratio was calculated as post-vaccination titer at Day 31 to pre-vaccination titer at Day 1.
| Ratio | Group 1: SP0202-IIb | Group 2: SP0202-VI | Group 3: SP0202-VII | Group 4: Prevnar 13 | Group 5: Pneumovax 23 |
|---|---|---|---|---|---|
| Serotype 1 | 5.39 (4.33 to 6.70) | 6.47 (5.27 to 7.95) | 6.41 (5.11 to 8.03) | 11.6 (9.21 to 14.6) | 11.5 (9.09 to 14.5) |
| Serotype 3 | 2.99 (2.49 to 3.61) | 4.02 (3.40 to 4.76) | 4.93 (4.07 to 5.97) | 3.86 (3.21 to 4.65) | 3.52 (3.01 to 4.12) |
| Serotype 4 | 6.52 (5.32 to 7.98) | 5.91 (4.93 to 7.07) | 7.33 (5.90 to 9.10) | 10.8 (8.71 to 13.3) | 5.47 (4.57 to 6.55) |
| Serotype 5 | 5.43 (4.32 to 6.82) | 5.81 (4.67 to 7.22) | 4.60 (3.75 to 5.66) | 10.6 (8.15 to 13.7) | 8.93 (7.15 to 11.1) |
| Serotype 6A | 13.8 (10.5 to 18.2) | 12.2 (9.79 to 15.3) | 12.6 (9.76 to 16.4) | 19.3 (14.9 to 24.9) | 3.30 (2.75 to 3.96) |
| Serotype 6B | 12.2 (9.31 to 16.0) | 9.63 (7.59 to 12.2) | 10.7 (8.10 to 14.0) | 16.2 (12.8 to 20.5) | 5.51 (4.51 to 6.74) |
| Serotype 7F | 10.6 (8.37 to 13.4) | 9.67 (7.86 to 11.9) | 7.93 (6.30 to 9.99) | 16.3 (12.8 to 20.7) | 6.80 (5.67 to 8.16) |
| Serotype 9V | 5.65 (4.59 to 6.95) | 6.29 (5.09 to 7.76) | 7.87 (6.28 to 9.86) | 9.12 (7.53 to 11.0) | 6.30 (5.17 to 7.68) |
| Serotype 14 | 4.91 (3.93 to 6.13) | 6.44 (5.06 to 8.19) | 4.62 (3.59 to 5.95) | 5.96 (4.68 to 7.58) | 7.35 (5.85 to 9.23) |
| Serotype 18C | 6.52 (5.26 to 8.08) | 7.18 (5.86 to 8.79) | 6.21 (5.09 to 7.58) | 12.1 (9.52 to 15.3) | 6.91 (5.74 to 8.31) |
| Serotype 19A | 4.74 (3.89 to 5.78) | 8.76 (7.14 to 10.7) | 7.86 (6.28 to 9.84) | 12.3 (9.79 to 15.4) | 5.74 (4.72 to 6.98) |
| Serotype 19F | 4.97 (4.02 to 6.15) | 11.2 (8.82 to 14.3) | 9.65 (7.53 to 12.4) | 11.2 (8.77 to 14.2) | 6.18 (5.07 to 7.53) |
| Serotype 23F | 13.2 (10.2 to 17.2) | 11.0 (8.75 to 13.9) | 11.9 (9.21 to 15.3) | 13.0 (10.3 to 16.4) | 5.70 (4.57 to 7.12) |
| Serotype 8 | 7.97 (6.41 to 9.92) | 8.44 (6.88 to 10.3) | 8.20 (6.54 to 10.3) | 1.26 (1.11 to 1.42) | 13.9 (11.5 to 16.8) |
| Serotype 9N | 6.52 (5.22 to 8.14) | 8.39 (6.67 to 10.5) | 9.99 (7.87 to 12.7) | 2.81 (2.36 to 3.35) | 11.3 (9.20 to 13.8) |
| Serotype 10A | 8.45 (6.74 to 10.6) | 10.0 (8.01 to 12.6) | 7.55 (5.83 to 9.78) | 1.15 (1.07 to 1.22) | 9.84 (7.98 to 12.1) |
| Serotype 11A | 5.57 (4.56 to 6.82) | 6.13 (5.08 to 7.38) | 5.36 (4.36 to 6.61) | 1.18 (1.10 to 1.27) | 5.54 (4.65 to 6.60) |
| Serotype 12F | 8.70 (6.66 to 11.4) | 9.47 (7.29 to 12.3) | 8.05 (6.20 to 10.5) | 1.08 (1.02 to 1.14) | 5.07 (4.01 to 6.40) |
| Serotype 15B | 7.77 (6.28 to 9.63) | 11.6 (9.13 to 14.7) | 8.74 (6.99 to 10.9) | 1.35 (1.19 to 1.52) | 9.87 (7.95 to 12.2) |
| Serotype 22F | 9.21 (7.38 to 11.5) | 10.0 (8.09 to 12.5) | 8.99 (7.32 to 11.0) | 1.09 (1.02 to 1.17) | 7.30 (5.95 to 8.95) |
| Serotype 33F | 4.54 (3.68 to 5.60) | 5.59 (4.58 to 6.81) | 4.43 (3.60 to 5.45) | 1.03 (0.981 to 1.08) | 9.43 (7.64 to 11.6) |
An unsolicited AE was an observed AE that did not fulfill the conditions of solicited reactions, i.e., pre-listed in the CRF in terms of diagnosis and/or onset window post-vaccination. Systemic AEs were all AEs that were not injection or administration site reactions.
| Participants | Group 1: SP0202-IIb | Group 2: SP0202-VI | Group 3: SP0202-VII | Group 4: Prevnar 13 | Group 5: Pneumovax 23 |
|---|---|---|---|---|---|
| Number of Participants With Immediate Unsolicited Systemic Adverse Events (AEs) | 0 | 0 | 1 | 0 | 0 |
A solicited reaction was an "expected" adverse reaction (AR) (sign or symptom) observed and reported under the conditions (nature and onset) pre-listed in the protocol and CRF. An injection site reaction was an AR at and around the injection site. Solicited injection site reactions included injection site pain, injection site erythema and injection site swelling.
| Participants | Group 1: SP0202-IIb | Group 2: SP0202-VI | Group 3: SP0202-VII | Group 4: Prevnar 13 | Group 5: Pneumovax 23 |
|---|---|---|---|---|---|
| Injection site pain | 106 | 113 | 107 | 85 | 74 |
| Injection site erythema | 17 | 25 | 19 | 3 | 9 |
| Injection site swelling | 14 | 19 | 14 | 4 | 6 |
A solicited reaction was an "expected" AR (sign or symptom) observed and reported under the conditions (nature and onset) pre-listed in the protocol and CRF. Solicited systemic reactions included fever, headache, malaise, myalgia, arthralgia and shivering.
| Participants | Group 1: SP0202-IIb | Group 2: SP0202-VI | Group 3: SP0202-VII | Group 4: Prevnar 13 | Group 5: Pneumovax 23 |
|---|---|---|---|---|---|
| Fever | 3 | 2 | 5 | 3 | 4 |
| Headache | 43 | 47 | 38 | 35 | 41 |
| Malaise | 36 | 43 | 30 | 28 | 32 |
| Myalgia | 57 | 71 | 56 | 49 | 65 |
| Arthralgia | 23 | 30 | 18 | 17 | 29 |
| Shivering | 20 | 27 | 18 | 7 | 13 |
An unsolicited AE was an observed AE that did not fulfill the conditions of solicited reactions, i.e., pre-listed in the CRF in terms of diagnosis and/or onset window post-vaccination.
| Participants | Group 1: SP0202-IIb | Group 2: SP0202-VI | Group 3: SP0202-VII | Group 4: Prevnar 13 | Group 5: Pneumovax 23 |
|---|---|---|---|---|---|
| Number of Participants With Unsolicited AEs | 21 | 34 | 19 | 18 | 20 |
An SAE was any untoward medical occurrence that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event. An AESI was defined as one of scientific and medical concern specific to the Sponsor's study intervention or program, for which ongoing monitoring and rapid communication by the investigator to the Sponsor could be appropriate. AESI included analyphylaxis.
| Participants | Group 1: SP0202-IIb | Group 2: SP0202-VI | Group 3: SP0202-VII | Group 4: Prevnar 13 | Group 5: Pneumovax 23 |
|---|---|---|---|---|---|
| SAEs | 3 | 7 | 3 | 2 | 2 |
| AESIs | 0 | 0 | 0 | 0 | 0 |
Collected over AEs, SAEs and all-cause mortality (deaths) were collected from the study vaccine administration (Day 1) until the end of 6-Month follow-up, 181 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group 1: SP0202-IIb | 0/151 (0%) | 3/151 (2%) | 113/151 (74.8%) |
| Group 2: SP0202-VI | 1/151 (0.7%) | 7/151 (4.6%) | 122/151 (80.8%) |
| Group 3: SP0202-VII | 1/148 (0.7%) | 3/148 (2%) | 112/148 (75.7%) |
| Group 4: Prevnar 13 | 0/149 (0%) | 2/149 (1.3%) | 102/149 (68.5%) |
| Group 5: Pneumovax 23 | 0/150 (0%) | 2/150 (1.3%) | 93/150 (62%) |
| Event | Group 1: SP0202-IIb | Group 2: SP0202-VI | Group 3: SP0202-VII | Group 4: Prevnar 13 | Group 5: Pneumovax 23 |
|---|---|---|---|---|---|
| Atrial FibrillationCardiac disorders | 0/151 | 1/151 | 1/148 | 0/149 | 0/150 |
| Covid-19 PneumoniaInfections and infestations | 1/151 | 1/151 | 1/148 | 0/149 | 0/150 |
| Subdural HaematomaInjury, poisoning and procedural complications | 0/151 | 0/151 | 1/148 | 0/149 | 0/150 |
| Acute Respiratory FailureRespiratory, thoracic and mediastinal disorders | 0/151 | 0/151 | 1/148 | 0/149 | 0/150 |
| Acute Myocardial InfarctionCardiac disorders | 0/151 | 0/151 | 0/148 | 1/149 | 0/150 |
| Small Intestinal ObstructionGastrointestinal disorders | 0/151 | 0/151 | 0/148 | 1/149 | 0/150 |
| PneumoniaInfections and infestations | 0/151 | 0/151 | 0/148 | 1/149 | 0/150 |
| Pneumonia AspirationInfections and infestations | 0/151 | 0/151 | 0/148 | 1/149 | 0/150 |
| DiverticulitisInfections and infestations | 0/151 | 0/151 | 0/148 | 0/149 | 1/150 |
| Cerebral HaemorrhageNervous system disorders | 0/151 | 0/151 | 0/148 | 0/149 | 1/150 |
| Event | Group 1: SP0202-IIb | Group 2: SP0202-VI | Group 3: SP0202-VII | Group 4: Prevnar 13 | Group 5: Pneumovax 23 |
|---|---|---|---|---|---|
| Injection Site PainGeneral disorders | 106/151 | 113/151 | 107/148 | 85/149 | 74/150 |
| MyalgiaMusculoskeletal and connective tissue disorders | 57/151 | 72/151 | 56/148 | 49/149 | 65/150 |
| HeadacheNervous system disorders | 43/151 | 48/151 | 38/148 | 36/149 | 42/150 |
| MalaiseGeneral disorders | 36/151 | 43/151 | 30/148 | 28/149 | 32/150 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 23/151 | 30/151 | 18/148 | 17/149 | 31/150 |
| ChillsGeneral disorders | 20/151 | 27/151 | 18/148 | 7/149 | 13/150 |
| Injection Site ErythemaGeneral disorders | 17/151 | 25/151 | 20/148 | 4/149 | 9/150 |
| Injection Site SwellingGeneral disorders | 14/151 | 19/151 | 14/148 | 4/149 | 6/150 |
Randomized population included all participants with data in the case report form (CRF).
| Age, Continuous(Years) | Group 1: SP0202-IIb | Group 2: SP0202-VI | Group 3: SP0202-VII | Group 4: Prevnar 13 | Group 5: Pneumovax 23 | Total |
|---|---|---|---|---|---|---|
| Mean | 63.3 ± 6.9 | 63.1 ± 6.6 | 62.9 ± 6.5 | 63.4 ± 6.8 | 63.1 ± 7.2 | 63.2 ± 6.8 |
| Sex: Female, Male(Participants) | Group 1: SP0202-IIb | Group 2: SP0202-VI | Group 3: SP0202-VII | Group 4: Prevnar 13 | Group 5: Pneumovax 23 | Total |
|---|---|---|---|---|---|---|
| Female | 76 | 84 | 78 | 86 | 93 | 417 |
| Male | 75 | 67 | 71 | 63 | 57 | 333 |
| Race/Ethnicity, Customized(Participants) | Group 1: SP0202-IIb | Group 2: SP0202-VI | Group 3: SP0202-VII | Group 4: Prevnar 13 | Group 5: Pneumovax 23 | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 2 | 1 | 0 | 4 |
| Black or African American | 19 | 17 | 24 | 10 | 13 | 83 |
| Native Hawaiian or other Pacific Islander | 0 | 1 | 0 | 1 | 0 | 2 |
| White | 120 | 123 | 113 | 127 | 121 | 604 |
| Asian | 10 | 9 | 9 | 10 | 11 | 49 |
| Multiple | 1 | 0 | 0 | 0 | 1 | 2 |
| Not reported | 0 | 1 | 1 | 0 | 4 | 6 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Ran from Oct 2020 to primary completion in Aug 2021, 10 months.
Results were first posted in Aug 2024, 3 years after primary completion. A results delay was requested in Aug 2022.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.